NCT03305133 (EPNEC) is a clinical trial of Immunohistochemistry in Large Cell Lung Cancer, sponsored by Groupe Francais De Pneumo-Cancerologie.

Who is sponsoring NCT03305133?

NCT03305133 is sponsored by Groupe Francais De Pneumo-Cancerologie.

What drugs are being tested in NCT03305133?

Interventions in NCT03305133: Immunohistochemistry.

What condition does NCT03305133 study?

NCT03305133 studies Large Cell Lung Cancer, Neuroendocrine Carcinoma of Lung (Diagnosis).

Is NCT03305133 still recruiting?

NCT03305133 is currently completed. Last updated 12 March 2020.

Last reviewed 2020-03-12 · How we verify

NCT03305133: EPNEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

Completed Last updated 12 March 2020

What this trial tests

trial testing Immunohistochemistry in Large Cell Lung Cancer in 86 participants. Completed in 30 October 2018.

Timeline

26 September 2017

Primary endpoint
14 September 2018

30 October 2018

Quick facts

Lead sponsor	Groupe Francais De Pneumo-Cancerologie
Status	Completed
Study type	OBSERVATIONAL
Enrollment	86
Start date	26 September 2017
Primary completion	14 September 2018
Estimated completion	30 October 2018
Sites	28 locations across France

Drugs / interventions tested

Immunohistochemistry — full drug profile →

Conditions studied

Large Cell Lung Cancer — all drugs for Large Cell Lung Cancer →
Neuroendocrine Carcinoma of Lung (Diagnosis) — all drugs for Neuroendocrine Carcinoma of Lung (Diagnosis) →

Sponsor

Groupe Francais De Pneumo-Cancerologie — full company profile →

Who can join

18 and older, any sex, with Large Cell Lung Cancer or Neuroendocrine Carcinoma of Lung (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expression in patients with large-cell lung neuroendocrine carcinoma (NEC), whatever the stage of the disease, and to correlate this parameter to clinical data at the time of diagnosis, therapeutic response and survival. Large-cell NECs present a bad prognostic and there is no evidence of treatment for these patients with advanced disease in second ligne of treatment at that time. To demonstrate the PD-L1 expression in this type of cancer might have a major therapeutic impact in a close future to access immunotherapies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Arpin D, Charpentier MC, Bernardi M, Monnet I, et al · · 2020 · cited 15× · PMID 32684990 · DOI 10.1177/1758835920937972
Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy.
Popper H, Brcic L. · · 2021 · cited 10× · PMID 34307132 · DOI 10.3389/fonc.2021.655752

Verify or expand the search:

Other trials of Immunohistochemistry

Trials testing the same drug.

NCT07319130 — Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 Exp · NA · enrolling by invitation
NCT07069842 — The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes · recruiting
NCT06657755 — Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients · completed
NCT06485193 — The Innate Immune Response and Enteric Nervous System in Crohn's Disease. · terminated
NCT05553080 — Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma · completed

Other recruiting trials for Large Cell Lung Cancer

Currently open trials in the same condition.

NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT01345851 — Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemother · NA · active not recruiting

Other Groupe Francais De Pneumo-Cancerologie trials

Trials by the same sponsor.

NCT06620835 — Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres · Phase 2 · recruiting
NCT06247826 — Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion · NA · recruiting
NCT05308966 — Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and I · completed
NCT05122806 — Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC · NA · recruiting
NCT05049044 — Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE) · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03305133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe Francais De Pneumo-Cancerologie
Last refreshed: 12 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03305133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing